What's happened
Purdue Pharma has reached a plan to dissolve the company and replace it with Knoa Pharma as a broad settlement resolving thousands of opioid lawsuits takes effect. The Sackler family’s contributions total up to $7 billion over 15 years, with most funds going to government entities to fight the opioid crisis. Individual victims will receive a smaller portion, while many observers urge greater accountability.
What's behind the headline?
What this means for victims and policy
- The settlement is among the largest in opioid-related litigation and centers on government-facing funding rather than solely individual restitution.
- Purdue's transformation into Knoa Pharma shifts liability toward the new entity and limits Sackler exposure to lawsuits tied to the payments.
- Prosecutors and advocates will assess whether the structure delivers meaningful accountability or primarily resolves litigation costs.
- The timing matters: the settlement could take effect within days, potentially accelerating funding for addiction services and prevention programs.
What to watch next
- How Knoa Pharma implements governance and what happens to existing Purdue documents slated for public release.
- Whether ongoing litigation or state actions add any new obligations for the Sackler family or Knoa Pharma.
- The actual distribution of payments to individual victims and the criteria used to determine qualifying claims.
How we got here
Purdue Pharma has faced criminal and civil probes over marketing and distribution of OxyContin. In 2020, the company admitted failures to prevent diversion, and it disclosed payments to doctors and to an electronic records firm that encouraged opioid prescriptions. A broad settlement has been approved by bankruptcy courts and involves the Sackler family transferring up to $7 billion over 15 years and the company reorganizing as Knoa Pharma to operate for public benefit.
Our analysis
The Guardian reports that Purdue Pharma has reached a plan to dissolve Purdue and replace it with Knoa Pharma, with Sackler family contributions up to $7bn over 15 years, most funds going to government entities to combat the opioid crisis. AP News notes a criminal sentence is required to finalize the settlement and outlines victims’ responses. Reuters provides detail on the individual compensation fund, citing about $865 million earmarked for victims and the procedural delays in claim validation. The Independent and The Guardian also cover objections from victims who seek greater accountability and potential criminal charges against Sackler family members.
Go deeper
- What assurances exist that Knoa Pharma will sustain funding for addiction services?
- How will individual victim payments be calculated and when will they begin?
- Are there any new obligations for Sackler family members beyond the agreed settlement?
More on these topics
-
Purdue Pharma - Pharmaceutical company
Purdue Pharma L.P. is a privately held pharmaceutical company founded by John Purdue Gray. It is owned principally by descendants of Mortimer and Raymond Sackler.
-
Sackler family - American billionaire family
The Sackler family is an American family who owned the pharmaceutical company Purdue Pharma and later founded Mundipharma. Purdue Pharma, and some members of the family, have faced lawsuits regarding over-prescription of addictive pharmaceutical drugs...